Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Evidence for tankyrases as antineoplastic targets in lung cancer

Authors: Alexander M Busch, Kevin C Johnson, Radu V Stan, Aarti Sanglikar, Yashi Ahmed, Ethan Dmitrovsky, Sarah J Freemantle

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

New pharmacologic targets are urgently needed to treat or prevent lung cancer, the most common cause of cancer death for men and women. This study identified one such target. This is the canonical Wnt signaling pathway, which is deregulated in cancers, including those lacking adenomatous polyposis coli or β-catenin mutations. Two poly-ADP-ribose polymerase (PARP) enzymes regulate canonical Wnt activity: tankyrase (TNKS) 1 and TNKS2. These enzymes poly-ADP-ribosylate (PARsylate) and destabilize axin, a key component of the β-catenin phosphorylation complex.

Methods

This study used comprehensive gene profiles to uncover deregulation of the Wnt pathway in murine transgenic and human lung cancers, relative to normal lung. Antineoplastic consequences of genetic and pharmacologic targeting of TNKS in murine and human lung cancer cell lines were explored, and validated in vivo in mice by implantation of murine transgenic lung cancer cells engineered with reduced TNKS expression relative to controls.

Results

Microarray analyses comparing Wnt pathway members in malignant versus normal tissues of a murine transgenic cyclin E lung cancer model revealed deregulation of Wnt pathway components, including TNKS1 and TNKS2. Real-time PCR assays independently confirmed these results in paired normal-malignant murine and human lung tissues. Individual treatments of a panel of human and murine lung cancer cell lines with the TNKS inhibitors XAV939 and IWR-1 dose-dependently repressed cell growth and increased cellular axin 1 and tankyrase levels. These inhibitors also repressed expression of a Wnt-responsive luciferase construct, implicating the Wnt pathway in conferring these antineoplastic effects. Individual or combined knockdown of TNKS1 and TNKS2 with siRNAs or shRNAs reduced lung cancer cell growth, stabilized axin, and repressed tumor formation in murine xenograft and syngeneic lung cancer models.

Conclusions

Findings reported here uncovered deregulation of specific components of the Wnt pathway in both human and murine lung cancer models. Repressing TNKS activity through either genetic or pharmacological approaches antagonized canonical Wnt signaling, reduced murine and human lung cancer cell line growth, and decreased tumor formation in mouse models. Taken together, these findings implicate the use of TNKS inhibitors to target the Wnt pathway to combat lung cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.CrossRefPubMed
3.
Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, Boer R, Gorlova O, Gazelle GS, Kimmel M, McMahon PM, De Koning HJ, Feuer EJ: Impact of reduced tobacco smoking on lung cancer mortality in the united states during 1975–2000. J Natl Cancer Inst. 2012, 104: 541-548.CrossRefPubMedPubMedCentral
4.
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011, 365: 395-409.CrossRefPubMed
5.
Yang P: Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005, 128: 452-462.CrossRefPubMed
6.
Snow GE, Kasper AC, Busch AM, Schwarz E, Ewings K, Bee T, Spinella MJ, Dmitrovsky E, Freemantle SJ: Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. BMC Cancer. 2009, 9: 383-CrossRefPubMedPubMedCentral
7.
You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM: Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004, 23: 6170-6174.CrossRefPubMed
8.
Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, DeMayo FJ, Morrisey EE: Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 2011, 121: 1935-1945.CrossRefPubMedPubMedCentral
9.
Nguyen DX, Chiang AC, Zhang XH-F, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J: WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis. Cell. 2009, 138: 51-62.CrossRefPubMedPubMedCentral
10.
11.
12.
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R, Ben-Ze’ev A: The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999, 96: 5522-5527.CrossRefPubMedPubMedCentral
13.
Lamlum H, Papadopoulou A, Ilyas M, Rowan A, Gillet C, Hanby A, Talbot I, Bodmer W, Tomlinson I: APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci USA. 2000, 97: 2225-2228.CrossRefPubMedPubMedCentral
14.
Johnson V, Lipton LR, Cummings C, Eftekhar Sadat AT, Izatt L, Hodgson SV, Talbot IC, Thomas HJW, Silver AJR, Tomlinson IPM: Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families. J Med Genet. 2005, 42: 756-762.CrossRefPubMedPubMedCentral
15.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 1997, 275: 1787-1790.CrossRefPubMed
16.
Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J: Constitutive activation of the Wnt signaling pathway by CTNNB1 (β‒catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer. 2001, 30: 316-321.CrossRefPubMed
17.
Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM: Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003, 22: 7218-7221.CrossRefPubMed
18.
Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM: Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004, 64: 4717-4720.CrossRefPubMed
19.
Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh J, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C: WIF1, a component of the Wnt pathway, is down‒regulated in prostate, breast, lung, and bladder cancer. J Pathol. 2003, 201: 204-212.CrossRefPubMed
20.
Huang S-MA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C: Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009, 461: 614-620.CrossRefPubMed
21.
Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan C-W, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009, 5: 100-107.CrossRefPubMedPubMedCentral
22.
Smith S, Giriat I, Schmitt A, De Lange T: Tankyrase, a Poly (ADP-Ribose) Polymerase at Human Telomeres. Science. 1998, 282: 1484-1487.CrossRefPubMed
23.
Chang P, Coughlin M, Mitchison TJ: Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol. 2005, 7: 1133-1139.CrossRefPubMed
24.
Chang P, Coughlin M, Mitchison TJ: Interaction between poly(ADP-ribose) and NuMA contributes to mitotic spindle pole assembly. Mol Biol Cell. 2009, 20: 4575-4585.CrossRefPubMedPubMedCentral
25.
Lu J, Ma Z, Hsieh J-C, Fan C-W, Chen B, Longgood JC, Williams NS, Amatruda JF, Lum L, Chen C: Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg Med Chem Lett. 2009, 19: 3825-3827.CrossRefPubMedPubMedCentral
26.
Karlberg T, Markova N, Johansson I, Hammarström M, Schütz P, Weigelt J, Schüler H: Structural Basis for the Interaction Between Tankyrase-2 and a Potent Wnt-Signaling Inhibitor. J Med Chem. 2010, 53: 5352-5355.CrossRefPubMed
27.
Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang L-Z, Webber SE, Curtin NJ: Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007, 6: 945-956.CrossRefPubMed
28.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12: 852-861.CrossRefPubMed
29.
Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH: Advances in using PARP inhibitors to treat cancer. BMC Med. 2012, 10: 25-CrossRefPubMedPubMedCentral
30.
Freemantle SJ, Dmitrovsky E: Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila). 2010, 3: 1513-1518.CrossRef
31.
Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E: Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA. 2007, 104: 4089-4094.CrossRefPubMedPubMedCentral
32.
Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E: Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009, 15: 1177-1183.CrossRefPubMedPubMedCentral
33.
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E: Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Mol Cancer Ther. 2012, 11: 1968-1977.CrossRefPubMedPubMedCentral
34.
Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V, Dmitrovsky E: Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene. 1996, 13: 1983-1990.PubMed
35.
Hendriksen J, Jansen M, Brown CM, Van Der Velde H, Van Ham M, Galjart N, Offerhaus GJ, Fagotto F, Fornerod M: Plasma membrane recruitment of dephosphorylated β-catenin upon activation of the Wnt pathway. J Cell Sci. 2008, 121: 1793-1802.CrossRefPubMed
36.
37.
Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen ISY, Hahn WC, Sharp PA, Weinberg RA, Novina CD: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003, 9: 493-501.CrossRefPubMedPubMedCentral
38.
Tomayko MM, Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989, 24: 148-154.CrossRefPubMed
39.
Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, DiRenzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E: MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010, 120: 1298-1309.CrossRefPubMedPubMedCentral
40.
Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E: Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res. 2010, 16: 109-120.CrossRefPubMed
41.
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E: Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in Two clinical trials and transgenic models. Cancer Prev Res (Phila). 2011, 4: 818-828.CrossRef
42.
Liu W, Shaver TM, Balasa A, Ljungberg MC, Wang X, Wen S, Nguyen H, Van den Veyver IB: Deletion of porcn in mice leads to multiple developmental defects and models human focal dermal hypoplasia (goltz syndrome). PLoS One. 2012, 7: e32331-CrossRefPubMedPubMedCentral
43.
Ahumada A, Slusarski DC, Liu X, Moon RT, Malbon CC, Wang H: Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP. Science. 2002, 298: 2006-2010.CrossRefPubMed
44.
Chan DW, Chan C-Y, Yam JWP, Ching Y-P, Ng IOL: Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology. 2006, 131: 1218-1227.CrossRefPubMed
45.
Yeh T-YJ, Meyer TN, Schwesinger C, Tsun Z-Y, Lee RM, Chi N-W: Tankyrase recruitment to the lateral membrane in polarized epithelial cells: regulation by cell-cell contact and protein poly(ADP-ribosyl)ation. Biochem J. 2006, 399: 415-425.CrossRefPubMedPubMedCentral
46.
Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J, Lowy AM: β-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002, 62: 3503-3506.PubMed
47.
Johnson V, Volikos E, Halford SE, Eftekhar Sadat ET, Popat S, Talbot I, Truninger K, Martin J, Jass J, Houlston R, Atkin W, Tomlinson IPM, Silver ARJ: Exon 3 β-catenin mutations are specifically associated with colorectal carcinomas in hereditary Non-polyposis colorectal cancer syndrome. Gut. 2005, 54: 264-267.CrossRefPubMedPubMedCentral
48.
Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA: The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010, 327: 1650-1653.CrossRefPubMedPubMedCentral
49.
Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL: β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer. 2004, 100: 2084-2092.CrossRefPubMed
50.
Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS: β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011, 24: 209-231.CrossRefPubMed
51.
Wu R, Zhai Y, Fearon ER, Cho KR: Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 2001, 61: 8247-8255.PubMed
52.
Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA: Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 2009, 28: 2163-2172.CrossRefPubMedPubMedCentral
53.
Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo J-A, Davis D, Kirkpatrick DS, Polakis P, Costa M: Ubiquitin ligase RNF146 regulates tankyrase and axin to promote Wnt signaling. PLoS One. 2011, 6: e22595-CrossRefPubMedPubMedCentral
54.
Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, Schirle M, Shi X, Hild M, Bauer A, Myer VE, Finan PM, Porter JA, Huang S-MA, Cong F: RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol. 2011, 13: 623-629.CrossRefPubMed
55.
Kirchhoff T, Chen Z, Gold B, Pal P, Gaudet MM, Kosarin K, Levine DA, Gregersen P, Spencer S, Harlan M, Robson M, Klein RJ, Hudis CA, Norton L, Dean M, Offit K: The 6q22.33 Locus and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2009, 18: 2468-2475.CrossRefPubMedPubMedCentral
56.
Menachem TD, Laitman Y, Kaufman B, Friedman E: The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women. Fam Cancer. 2009, 8: 399-402.CrossRefPubMed
57.
Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006, 5: 997-1014.CrossRefPubMed
58.
Karner CM, Merkel CE, Dodge M, Ma Z, Lu J, Chen C, Lum L, Carroll TJ: Tankyrase is necessary for canonical Wnt signaling during kidney development. Dev Dyn. 2010, 239: 2014-2023.CrossRefPubMedPubMedCentral
59.
Bao R, Christova T, Song S, Angers S, Yan X, Attisano L: Inhibition of tankyrases induces axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One. 2012, 7: e48670-CrossRefPubMedPubMedCentral
60.
Kirby CA, Cheung A, Fazal A, Shultz MD, Stams T: Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012, 68: 115-118.CrossRefPubMedPubMedCentral
61.
Narwal M, Haikarainen T, Fallarero A, Vuorela PM, Lehtiö L: Screening and structural analysis of flavones inhibiting tankyrases. J Med Chem. 2013, 56: 1341-1345.CrossRef
62.
Narwal M, Venkannagari H, Lehtiö L: Structural basis of selective inhibition of human tankyrases. J Med Chem. 2012, 55: 1360-1367.CrossRefPubMed
63.
Yang Y, Mallampati S, Sun B, Zhang J, Kim S-B, Lee J-S, Gong Y, Cai Z, Sun X: Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett. 2013, 333: 9-17.CrossRefPubMed
64.
Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, Krauss S: A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012, 72: 2822-2832.CrossRefPubMed
65.
Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M: A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2012, 72: 2822-2832.CrossRef
66.
Hsiao SJ, Smith S: Tankyrase function at telomeres, spindle poles, and beyond. Biochimie. 2008, 90: 83-92.CrossRefPubMed
67.
Lyons RJ, Deane R, Lynch DK, Ye Z-SJ, Sanderson GM, Eyre HJ, Sutherland GR, Daly RJ: Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14. J Biol Chem. 2001, 276: 17172-17180.CrossRefPubMed
68.
Nakashima N, Liu D, Huang C, Ueno M, Zhang X, Yokomise H: Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer. 2012, 76: 228-234.CrossRefPubMed
69.
Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr H-A, Delaloye J-F, Huelsken J: Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012, 481: 85-89.CrossRef
70.
DiMeo TA, Anderson K, Phadke P, Fan C, Feng C, Perou CM, Naber S, Kuperwasser C: A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69: 5364-5373.CrossRefPubMedPubMedCentral
71.
Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DCF, Tan AC, DeGregori J: Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012, 72: 4154-4164.CrossRefPubMedPubMedCentral
Metadata
Title
Evidence for tankyrases as antineoplastic targets in lung cancer
Authors
Alexander M Busch
Kevin C Johnson
Radu V Stan
Aarti Sanglikar
Yashi Ahmed
Ethan Dmitrovsky
Sarah J Freemantle
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-211

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression

Research article

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls

Research article

Napsin A as a marker of clear cell ovarian carcinoma

Research article

Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia

Research article

Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma

Research article

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits